Edwards Lifesciences (NYSE:EW) had words of praise and caution about a proposed reimbursement scheme for its Sapien transcatheter aortic valve implant unveiled by the Centers for Medicare & Medicaid Services last month.
Edwards, which boasts the only TAVI device cleared for the U.S. market, asked Medicare to reconsider limiting future clinical trials and asked the agency to re-think proposed rules for procedure credentialing focused on individual physicians.